AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 EpizymeZymeworksAkcea TherapeuticsTheravance BiopharmaSAGE Therapeutics
SymbolNASDAQ:EPZMNYSE:ZYMENASDAQ:AKCANASDAQ:TBPHNASDAQ:SAGE
Price Information
Current Price$17.46$38.87$15.09$26.54$34.80
52 Week RangeBuyBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.62.11.21.51.6
Analysis Score3.43.53.43.44.3
Community Score2.82.82.42.43.1
Dividend Score0.00.00.00.00.0
Ownership Score1.04.00.01.00.0
Earnings & Valuation Score0.60.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$30.71$50.73$34.67$37.00$82.11
% Upside from Price Target75.91% upside30.50% upside129.73% upside39.41% upside135.95% upside
Trade Information
Market Cap$1.73 billion$1.69 billion$1.53 billion$1.59 billion$1.80 billion
Beta2.051.161.241.472.67
Average Volume991,334454,125244,638400,1881,120,614
Sales & Book Value
Annual Revenue$23.80 million$29.54 million$488.54 million$73.41 million$6.87 million
Price / Sales74.1459.923.1222.81262.99
CashflowN/AN/A$0.52 per shareN/AN/A
Price / CashN/AN/A29.19N/AN/A
Book Value$3.22 per share$6.24 per share$5.78 per share($3.94) per share$18.23 per share
Price / Book5.426.232.61-6.741.91
Profitability
Net Income$-170,290,000.00$-145,440,000.00$40.77 million$-236,460,000.00$-680,240,000.00
EPS($1.93)($3.83)$0.48($4.25)($13.38)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-1,111.58%-629.37%-8.59%-280.80%-7,406.75%
Return on Equity (ROE)-67.19%-46.17%-6.70%N/A-63.13%
Return on Assets (ROA)-48.52%-35.82%-5.92%-47.43%-56.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.22%0.01%0.03%N/A0.03%
Current Ratio14.81%6.92%12.63%5.45%12.77%
Quick Ratio14.74%6.92%12.25%5.45%12.77%
Ownership Information
Institutional Ownership Percentage90.43%72.00%20.15%88.47%N/A
Insider Ownership Percentage16.30%4.20%1.50%5.90%4.80%
Miscellaneous
Employees124180248363637
Shares Outstanding101.06 million45.54 million101.07 million63.09 million51.92 million
Next Earnings Date8/14/2020 (Estimated)8/7/2020 (Estimated)8/4/2020 (Estimated)7/29/2020 (Estimated)8/4/2020 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.